Why Do Many Solid Tumor Treatments Still Rely on Infusion Therapy? The 2026 Landscape of Oncology Injection-Based Treatments

Explore why intravenous infusion remains the foundation of modern solid tumor treatment. Learn how ADCs, PD-1 immunotherapy, bispecific antibodies, and cell therapies are reshaping oncology in 2026.

Top Stories

Latest Coverage

CAR-T Therapy for Head and Neck Cancer: Challenges, Clinical Progress, and Future Perspectives
Learn why CAR-T therapy has revolutionized blood cancer treatment but remains challenging for head and neck cancer. E...
What Is the Survival Rate of Medulloblastoma? Key Factors Affecting Prognosis
Discover how molecular classification, surgery, radiotherapy, chemotherapy, and multidisciplinary care influence surv...
Advances in HER3 ADC Development for Head and Neck Squamous Cell Carcinoma (HNSCC): Latest Clinical Research and Future Perspectives
HER3-targeted antibody-drug conjugates are emerging as one of the most promising next-generation therapies for HNSCC....
PD-1 Drugs for Head and Neck Cancer: Globally Approved Therapies, Clinical Advances, and Future Development Trends
PD-1 inhibitors have transformed the treatment of head and neck squamous cell carcinoma. Learn about globally approve...
Current Status of Solid Tumor Treatment in China (2026): A Comprehensive Guide for International Patients Seeking Cancer Care in China
As global cancer treatment rapidly evolves toward precision medicine, personalized therapy, and long-term disease con...
What Advanced Cancer Therapies Are Available in China? Which International Patients Are They Suitable For?
As more international patients begin exploring cancer treatments in China, the demand for cross-border medical care c...

In-Depth Analysis


This site uses Just the Docs, a documentation theme for Jekyll.